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TINF2, a Component of the Shelterin Telomere Protection
Complex, Is Mutated in Dyskeratosis Congenita
Sharon A. Savage,1,* Neelam Giri,1 Gabriela M. Baerlocher,2,4 Nick Orr,3 Peter M. Lansdorp,4
and Blanche P. Alter1
Patients with dyskeratosis congenita (DC), a heterogeneous inherited bone marrow failure syndrome, have abnormalities in telomere
biology, including very short telomeres and germlinemutations inDKC1, TERC, TERT, orNOP10, but ~60% of DC patients lack an iden-
tiﬁable mutation. With the very short telomere phenotype and a highly penetrant, rare disease model, a linkage scan was performed on
a family with autosomal-dominant DC and no mutations in DKCI, TERC, or TERT. Evidence favoring linkage was found at 2p24 and
14q11.2, and this led to the identiﬁcation of TINF2 (14q11.2) mutations, K280E, in the proband and her ﬁve affected relatives and
TINF2R282H in three additional unrelatedDCprobands, includingonewithRevesz syndrome; a ﬁfthDCprobandhad aR282Smutation.
TINF2mutations were not present in unaffected relatives, DC probands withmutations inDKC1, TERC, or TERTor 298 control subjects.
We demonstrate that a ﬁfth gene, TINF2, is mutated in classical DC and, for the ﬁrst time, in Revesz syndrome. This represents the ﬁrst
shelterin complex mutation linked to human disease and conﬁrms the role of very short telomeres as a diagnostic test for DC.Dyskeratosis congenita (DC) is an inherited bone marrow
failure syndrome (IBMFS) characterized by the diagnostic
triad of abnormal nails, lacey reticular pigmentation, and
oral leukoplakia. Patients with DC are at high risk of
developing aplastic anemia, myelodysplastic syndrome,
and leukemia. Less common physical ﬁndings include epi-
phora, premature gray hair, developmental delay, short
stature, cerebellar hypoplasia, microcephaly, esophageal
stenosis, urethral stenosis, pulmonary ﬁbrosis, liver dis-
ease, avascular necrosis of hips or shoulders, and epithelial
cancers.1–3 Hoyeraal-Hreidarsson (HH) syndrome is a severe
form of DC with bone-marrow failure, immunodeﬁciency,
microcephaly, cerebellar hypoplasia, intrauterine growth
retardation, and developmental delay.2,4 Revesz syndrome,
characterized by bilateral exudative retinopathy, bone-
marrow hypoplasia, nail dystrophy, ﬁne hair, cerebellar
hypoplasia, and growth retardation, also appears to be in
the DC disease spectrum.5,6
This clinical heterogeneity has made the diagnosis of DC
challenging; many cases of DC are not diagnosed until the
development of cytopenias. DC patients with aplastic ane-
mia do not respond to immunosuppressive therapy,7 and if
bone-marrow transplantation is required, they are at high
risk of treatment-related complications because of under-
lying pulmonary and liver disease.8–11 Selection of related
bone-marrow donors may be complicated by the variable
phenotype seen in DC, including silent carriers.
The unifying feature present in all patients with DC is
abnormally short telomere lengths and defects in telomere
biology.1,12 Short telomeres were ﬁrst noted in primary
ﬁbroblasts and lymphoblasts of males with DKC1 muta-
tions.13 Subsequent studies have conﬁrmed that telomeres
are extremely short in DC patients and appear to shortenThe Amefurther in successive generations of affected individuals
from dominant families.14,15 Recently, very short telomere
lengths in leukocyte subsets, deﬁned as less than the ﬁrst
percentile for age, were found to be diagnostic of DC in
comparison to other IBMFS.12
Telomeres, which consist of long TTAGGG nucleotide
repeats and associated proteins at chromosome ends, are
essential for the maintenance of chromosomal integrity.16
In order to preserve the chromosome end, the telomerase
reverse transcriptase (TERT, MIM #187270), its RNA com-
ponent, TERC (also known as hTR, 3q21–q28, MIM
#602322), and an ordered protein complex, termed shel-
terin, consisting of six proteins (gene names TERF1 [MIM
#600951], TERF2 [MIM #602027], TINF2 [MIM #604319],
TERF2IP [MIM #605061], ACD [MIM #609377], and
POT1 [MIM #606478]) protect the telomere from end-to-
end fusion.16–18 Telomeric repeats are lost with each cell
division, in part because of incomplete replication of the
30 end of the chromosome. Telomeric attrition can result
in critically short telomeres prompting cellular senescence
or cellular crisis, including apoptosis, genomic instability,
or a reduction in cellular lifespan.19,20
DC family pedigrees indicate X-linked recessive (XLR),
autosomal dominant (AD), and autosomal recessive (AR)
inheritance.15 X-linked mutations have been identiﬁed
in dyskerin,DKC1 (MIM #300126). AD DC has been linked
to mutations in the RNA subunit of telomerase, TERC.21,22
Mutations in TERT have been identiﬁed in patients with
DC and those with aplastic anemia without the classical
DC triad.14,23,24 AR inheritance of mutations in NOP10
(gene name NOLA3, MIM #606471), a component of
H/ACA snoRNP complexes, was identiﬁed in one consan-
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300 DC patients, ~60% remain unclassiﬁed at the mole-
cular level.26
We identiﬁed a family with AD inheritance, variable
clinical phenotype, and no mutations in DKCI, TERC, or
TERT (family A) among the families with DC followed at
the National Cancer Institute (NCI) as part of the IRB-
approved study entitled ‘‘Etiologic Investigation of Cancer
Susceptibility in Inherited Bone Marrow Failure Syn-
dromes.’’ Evaluation of this family and of all others
described in this report included review of medical records,
careful physical examination, complete blood counts, bone
marrow studies, measurement of telomere length,12,27 and
mutation analyses. The diagnosis of DC, HH, or Revesz
syndrome was made according to the deﬁnitions of
Vulliamy et al.2 In brief, DC patients had at least two of
the three components of the triad or one of the triad
with either a hypoplastic bone marrow or at least two of
the other somatic features.
Telomere length was measured in white blood cell
subsets by automated multicolor ﬂow-FISH analysis of
granulocytes, CD45RAþ lymphocytes (naive T cells),
CD45RA lymphocytes (memory T cells), CD20þ lympho-
cytes (B cells), CD57þ lymphocytes (NK/NKT cells), and to-
tal leukocytes and compared with age-matched controls.27
‘‘Very short’’ was deﬁned as less than the ﬁrst percentile for
age.12 Germline DNA was isolated from buccal cells or pe-
ripheral blood white cells by standard methods. Mutation
analyses of DKC1 and TERC were performed by GeneDx
(Gaithersburg, MD) on the basis of cDNA reference se-
quences NM_001363.2 and U86046.1, as previously
described.28 The proximal promoter and all coding regions
of TERT were sequenced as described.29 All sequence anal-
yses were veriﬁed at least twice.502 The American Journal of Human Genetics 82, 501–509, FebruaryFamily A is nonconsanguineous and of European an-
cestry (Figure 1). III-07 was the proband. The ﬁrst cases
of DC in this family were monozygotic twin brothers,
II-01 and II-03. Telomere lengths were determined in all
22 living family members (Figure 2A). I-01 and I-02,
the paternal grandparents of the proband, were clinically
unaffected and had normal telomere lengths. Their other
children (generation 2) included ﬁve daughters and three
sons with normal telomere lengths. There was no other
family history of cancer, anemia, skin abnormalities, or
other features of DC. II-01 died at age 37 from aplastic
anemia and pulmonary hemorrhage. He and his wife
had ﬁve sons and one miscarriage. Two sons, III-01 and
III-03, and their mother were clinically unaffected and
had normal telomere lengths. His other three sons, III-
02, III-04, and III-05, had telomere lengths less than
the ﬁrst percentile, all three features of the diagnostic
triad, epiphora, and variable hematopoietic involvement
(Table 1).
II-03 died at age 43 because of aplastic anemia, non-
Hodgkin lymphoma, and pulmonary failure. He and his
wife had two daughters, III-06 and III-07, and three sons,
III-08, III-09, and III-10. III-06, III-09, and their mother
had no clinical signs of DC and normal telomere lengths
(Figure 2A). The other three children had telomere lengths
less than the ﬁrst percentile and variable phenotypes (Table
1). The proband, III-07, had severe aplastic anemia since
age 10, and thereby required a stem cell transplant at
age 29, but only subtle ﬁngernail ridging. III-08 had abnor-
mal nails (but had a history of frostbite at age 2 years),
premature gray hair, and penile leukoplakia but normal
blood counts; he did not meet the clinical deﬁnition of
DC but had very short telomere lengths. III-10 had noFigure 1. Pedigree of Family A
The monozygotic twins in generation II had five sisters and three brothers. Telomere length was determined on individuals except where
indicated by a star.2008
clinical signs of DC or bone marrow failure; however, his
telomere lengths were less than the ﬁrst percentile at age
13. Therefore, III-08 and III-10 were classiﬁed as silent
carriers.
An SNP genome-wide linkage screen was conducted with
genomic DNA samples from family A (Figure 1). Individ-
uals genotyped were I-01, I-02, II-02, II-04, and III-01
through III-10. Genotyping was performed at the NCI’s
Core Genotyping Facility. All samples were quantiﬁed
Figure 2. Lymphocyte Telomere Lengths
(A) Lymphocyte telomere lengths measured by flow-FISH of
family A, including generation III affected individuals (red filled
squares), generation III silent carriers (red open squares), unaf-
fected members of generation III (blue filled diamonds), and un-
affected members of generations I and II (blue open diamonds).
The black line indicates the first percentile, and the blue line indi-
cates the 99th percentile. Individual III-05 (filled red square on
the first percentile line) had telomere lengths of 5.2 kb. The first
percentile for age is 5 kb. However, his telomere lengths were
less than the first percentile for age in naive T cells and granulo-
cytes (data not shown).
(B) Lymphocyte telomere lengths of the four unrelated DC pro-
bands (filled red circles) with TINF2 mutations, their unaffected
parents (open blue diamonds), and unaffected siblings (filled
blue diamonds).The Ameand evaluated by Identiﬁler (Applied Biosystems, Carlsbad,
CA) so that duplicated or contaminated samples could be
ruled out. The 6008 SNP markers of the Human Linkage
IVb Panel (Illumina, San Diego, CA) were genotyped ac-
cording to the manufacturer’s instructions. The overall ge-
notype completion rate was R99% for all chromosomes.
Progeny Lab software (version 5, Progeny Software, LLC,
South Bend, IN) was used for processing genotype data.
With cutoffs of D0 ¼ 0.7 and R2 ¼ 0.4, SNPLINK was used
for evaluating and removing SNPs that were in linkage dis-
equilibrium with each other.30 After SNPLINK processing,
GeneHunter31 was used for analysis of the data under
a parametric, AD, rare, highly penetrant disease (0.00001
disease frequency, penetrance of 1.0) model with telomere
length less than the ﬁrst percentile as the affected pheno-
type. Evidence favoring linkage was found at two locations,
a 17.6 megabase (Mb) region on chromosome 2p24 and a
2.8 Mb region on chromosome 14q11.2 (LOD score ¼ 2.62
at both sites) (Table 2 and Figure 3).
The strongest candidate gene at chromosome 2p24 was
DDX1 (DEAD [Asp-Glu-Ala-Asp] box polypeptide 1, MIM
#601257), an RNA helicase that is involved in pre-mRNA
processing and RNA unwinding.32 Primers for DDX1 were
designed with the NCI’s Oncogenomics database. Primer
sequences and annealing temperatures are available upon
request. Genomic DNA was ampliﬁed by PCR with MJ Re-
search model PTC-225 thermal cyclers (Bio-Rad Laborato-
ries, Waltham, MA) with the following conditions: 10 ng
of genomic DNA, 0.2 mM of each primer (appended with
M13 tags), 200 mM of each dNTP, 2 mM MgCl2, 0.5 units
AmpliTaq Gold DNA polymerase (ABI-Perkin Elmer, Foster
City, CA), and the manufacturer’s buffer. Bidirectional
sequencing of ampliﬁed DNA with the Dye Terminator
method (ABI-Perkin Elmer) and M13 forward and reverse
primers was analyzed on ABI-Perkin Elmer platforms
(models 3730 or 3700) with Sequence Analysis 3.7 software
and Sequencher v4.6 software (Gene Codes Corporation,
Ann Arbor, MI).
No mutations were identiﬁed in the coding regions of
all 20 exons of DDX1 in the proband III-07. Three com-
mon SNPs were identiﬁed, rs2302929, rs10929378, and
rs10221770, in III-07 and were also present in the dbSNP
database.
The strongest candidate gene at chromosome 14q11.2
was TINF2 (MIM #604319), TERF1 (TRF1)-interacting nu-
clear factor 2 (protein name TIN2), a 6 exon gene whose
protein product (TIN2) binds to telomeric repeat binding
factors 1 and 2 (TRF1 and TRF2). Therefore, bidirectional
sequence analysis on genomic DNA from the proband
was performed on TINF2 as described.29 Sequence analysis
of 298 healthy control individuals (596 chromosomes) was
performed when a possible mutation was identiﬁed. Con-
trols were derived from the SNP500Cancer Panel33 and Hu-
man Variation Panels HD100AA and HD100CA from Cor-
iell Cell Repositories. Their self-identiﬁed ethnicities were
118 African Americans, 125 Caucasians, 32 Asian/Paciﬁc
Rim, and 23 Hispanic.rican Journal of Human Genetics 82, 501–509, February 2008 503
The proband, III-07, was heterozygous for an A-to-Gmu-
tation at Ex6þ234 in TINF2, and this results in a change
from lysine to glutamic acid at amino acid 280 (K280E)
(Figure 4). Sequence analysis of the individuals who were
part of the linkage scan from family A showed that this
mutation was present only in individuals who had telo-
mere lengths less than the ﬁrst percentile, III-02, III-04,
III-05, III-07, III-08, and III-10. Speciﬁcally, I-01 and I-02,
the paternal grandparents of the proband, did not have
this mutation. It probably arose as a previously unrecog-
nized mutation in their monozygotic twin sons, II-01
and II-03; however, we were unable to verify this because
of the absence of archival tissue from the deceased twins.
This mutation was not identiﬁed in the sequence analysis
of genomic DNA from 298 healthy individuals.
The presence of TINF2 mutations only in individuals
from family A with very short telomeres prompted the504 The American Journal of Human Genetics 82, 501–509, Februaryevaluation of all DC patients that were available for analy-
ses. TINF2was sequenced in an additional 15 DC probands
with very short telomeres. Eight of these patients had no
detectable mutations in DKC1, TERC, or TERT, three had
DKC1 mutations, three had TERC mutations and one
had a TERTmutation. Half (8 out of 16 total) of the DC pa-
tients were molecularly uncharacterized, consistent with
previous estimates by others.26 TINF2 was not mutated in
DC probands with mutations in DKC1, TERC, or TERT.
In addition, common SNPs in TINF2 were not identiﬁed
in any DC probands.
Heterozygous TINF2 mutations were identiﬁed in four
of the eight previously molecularly uncharacterized pro-
bands (normal DKC1, TERC, or TERT) with very short telo-
meres (Table 1 and Figures 2B and 3) but not in any of the
298 controls. Three probands, B-1, C-1, and D-1, shared













Features WBC/mm3 ANC/mm3 Hbg/dl MCVfL
Platelets
3103/mm3 Mutation
A-II-01M DC 13 NA þ þ þ SAA, bilateral hip AVN,
urethral strictures, died
from pulmonary
hemorrhage at age 37
2100 945 9.7 105 23 K280E
A-II-03M DC 16 NA NA þ þ SAA bilateral hip AVN,
died from NHL at
age 43
1800 774 6 120 27 K280E
A-III-02M DC 31 31 þ þ þ epiphora 4300 2209 15.1 96.2 142 K280E
A-III-04M DC 24 24 þ þ þ epiphora 3400 1582 14.8 98.3 108 K280E
A-III-05M DC 12 21 þ þ þ epiphora, reduced DLCO 3200 1909 11.6 109 23 K280E
A-III-07F DC 10 27 þ þ þ SAA, matched sibling
BMT, epiphora
2200 828 7.8 118 7 K280E
A-III-08M Silent
Carrier
26 26  b  gray hair, penile
leukoplakia
3400 1816 14.6 94 148 K280E
A-III-10M Silent
Carrier
13 13    reduced DLCO 3290 1414 13.9 88.1 188 K280E






4400 1496 9.9 89.7 28 R282H





2200 1453 7.9 111 36 R282H
D-1M DC 2.8 3.7  þ  SAA, IgA deficiency 2900 435 10.3 89.6 47 R282H
E-1F DC 3.2 9.5 þ þ þ SAA, epiphora, reduced
DLCO, decreased NK
cell number
2000 629 10.4 87.9 21 R282S
All patients listed had telomere lengths less than the first percentile for age as measured by multicolor flow-FISH. Abbreviations are used as follows:
DC, dyskeratosis congenita; RS, Revesz syndrome; M, male; F, female; NA, not available because patients died prior to study; WBC, white blood cell count;
ANC, absolute neutrophil count; Hb, hemoglobin; MCV, mean corpuscular volume; SAA, severe aplastic anemia; AVN, avascular necrosis; NHL, Non-Hodgkin
lymphoma; DLCO, diffusion capacity of the lung for carbon monoxide; BMT, bone-marrow transplant; and NK cell, natural killer cell.
a Age when patient first presented to a physician with clinical findings that were suspicious for DC.
b This patient had severe frostbite of fingers and toes at age 2, and thus we could not evaluate nail dystrophy.2008
acid 282 (R282H, Ex6þ241G/A). The fourth proband,
E-1, had a different mutation at amino acid 282, arginine
to serine (R282S, Ex6þ240C/A).
Proband B-1 had the DC triad, very short telomeres,
thrombocytopenia, intrauterine growth retardation, and
speech delay. He developed severe aplastic anemia at 3.7
years of age. His unaffected mother had normal telomere
lengths and no mutation in TINF2. His father and brother
were clinically unaffected, but blood was not available for
telomere length measurement or mutation testing.
Proband C-1 had Revesz syndrome with the characteris-
tic bilateral exudative retinopathy, the DC triad, develop-
mental delay, cerebellar hypoplasia, and very short telo-
mere lengths. Severe aplastic anemia developed at age 1.5
years. His unaffected parents and one sister had normal
telomere lengths and no mutation in TINF2. A second sis-
ter had normal telomere lengths, but DNA was not avail-
able for sequence analysis.
Proband D-1 did not have the DC diagnostic triad but
did have dystrophic nails, very short telomeres, and IgA
deﬁciency. Severe aplastic anemia developed at 2.8 years
of age. He had no siblings; his parents had normal telomere
lengths with no mutation in TINF2.
The proband with the R282S TINF2 mutation, E-1, was
unsuccessfully treated with two courses of immunosup-
pressive therapy for acquired severe aplastic anemia, ﬁrst
diagnosed at age 3.2 years, before the classic nail, skin,
Table 2. Linkage-Scan Results
























A SNP linkage scan was performed on family A as described. Linkage
disequilibrium between SNPs was removed with SNPLINK, and GeneHunter
was used for analysis of the data under an autosomal-dominant, rare
disease model with telomere length less than the first percentile as the
affected phenotype. The maximum LOD scores for each chromosome are
shown. Statistically significant scores are shown in bold type.The Ameand oral ﬁndings of DC were identiﬁed. She had very short
telomeres and reduced numbers of natural killer cells. Her
parents and sister were healthy, did not have a TINF2
mutation, and had normal telomere lengths.
TINF2, like many genes important in telomere biology,
has limited nucleotide diversity and is highly evolution-
arily conserved.29 It has been suggested that mutations in
highly conserved genomic regions are more likely to be
pathogenic.34 Therefore, the degree of evolutionary con-
servation in the mutated region of TINF2 was further eval-
uated with mVISTA alignments.35 Figure 5A shows the
high level of evolutionary conservation between human
and mouse TINF2 genomic sequences. Comparisons of
Figure 3. LOD Scores for Chromosomes 2 and 14
LOD scores were determined under an autosomal-dominant (para-
metric), rare disease model with telomere length less than the first
percentile as the affected phenotype as described in the text. The
relative location of the markers is noted on the x axis.
(Top) A total of 356 SNP markers on chromosome 2 were evaluated
after removal of SNPs in linkage disequilibrium as described. The
maximum LOD score of 2.62 was located between SNPmarkers rs6767
and rs520354 on chromosome 2 at positions 3.5 Mb and 21.1 Mb, re-
spectively. DDX1 was the best candidate gene in this location.
(Bottom) A total of 161 SNP markers on chromosome 14 were eval-
uated after removal of SNPs in linkage disequilibrium as described.
The maximum LOD score of 2.62 was located between SNP markers
rs1570342 and rs195677 on chromosome 14 at positions 22.4 Mb
and 25.2 Mb, respectively. TINF2 was the best candidate gene in
this location.rican Journal of Human Genetics 82, 501–509, February 2008 505
the genomic and protein sequences of TINF2 between
humans andﬁve other species, chimpanzee (Pan troglodytes),
mouse (Mus musculus), rat (Rattus norvegicus), dog (Canis
lupus familiaris), and cow (Bos taurus), are shown in Figures
5B and 5C, respectively. The nucleotides that weremutated
Figure 4. Representative Sequence Tracings of TINF2 Muta-
tions
The proband and mutation are noted above the sequence tracing.506 The American Journal of Human Genetics 82, 501–509, Februaryin DC patients, Ex6þ234A/G, Ex6þ240C/A, and Ex6þ
241G/A, are conserved between all six species. Amino
acids 279–287 are also conserved between the six species
evaluated.
In silico analyses were performed for predicting the
possible functional effects of TINF2mutations with sorting
intolerant from tolerant (SIFT).36 SIFT predicted that all
three mutations, K280E, R282H, and R282S, would not
be tolerated. Exonic splicing enhancers (ESEs) were identi-
ﬁed with ESEFinder37 and RESCUE-ESE38 (Figure 5B). An
AAGGAG hexamer is present, beginning at Ex6þ234 (start
of codon 280). The mutation at that site changes the puta-
tive ESE to GAGGAG in addition to the K280E mutation in
family A. The Ex6þ240C/A (start of codon 282) mutation
was predicted to potentially alter the SF2/ASF motif by
changing CGCCCCA to AGCCCCA in addition to the
R282S coding mutation. Ex6þ241G/A, at the second
site of this motif and the R282H mutation, may have a
weaker effect.
It is also notable that the mutated amino acids are
located in extremely close proximity, positions 280 and
282; amino acid 282 was mutated in four patients. A re-
combination or mutation ‘‘hot spot’’ that is undeﬁned at
this time is theoretically possible in this region. This possi-
bility, in combination with in silico predictions of the del-
eterious effects of these mutations, and the high degree of
evolutionary conservation of this region of TINF2, suggestsFigure 5. Genomic Structure and Evolutionary Conservation of TINF2
(A) The genomic region of TINF2 consists of 2686 base pairs. The red arrows show the relative positions of the mutations identified in the
DC patients in this study, Ex6þ234A/G (K280E), Ex6þ240C/A (R282S), and Ex6þ241G/A (R282H). Curves showing conservation
between human and mouse genomic sequences were generated with VISTA. On the right, 50% and 75% conservation are noted. Exons
are shown in blue, and the conserved 30 untranslated region is shown in light blue.
(B) Comparison of nucleotide conservation between Homo sapiens (Entrez Gene Annotation, NC_000014.7), Pan troglodytes
(NC_006481.2), Mus musculus (NC_00080.5), Rattus norvegicus (NC_005114.2), Canis lupus familiaris (NC_006590.2), and Bos taurus
(NC_007308.2) TINF2 genomic sequences between Ex6þ204 through Ex6þ272. Conserved nucleotides are shown in yellow. Mutated
nucleotides are noted with red arrows. The blue lines above the nucleotides indicate putative exonic splice enhancer (ESE) sequences.
(C) Comparison of amino acid conservation between Homo sapiens (Entrez Protein Annotation, NP_036593.1), Pan troglodytes
(CAH89509.1, hypothetical protein TIN2), Mus musculus (NP_663751.2), Rattus norvegicus (NP_001006963.1), Canis lupus familiaris
(XP_850486.1, predicted protein), and Bos taurus (XP_593926.3, predicted protein) between amino acids 270 and 292. Conserved amino
acids are noted in yellow. Mutated amino acids K280E, R282S, and R292H are noted at the bottom.2008
that these mutations are deleterious and probably contrib-
ute to the telomere abnormalities and phenotypes seen in
our DC patients with TINF2 mutations.
The protein product of TINF2, TIN2, is a central compo-
nent of shelterin, the protein complex that stabilizes telo-
meres.17 TIN2 connects the three primary DNA-binding
proteins, TRF1, TRF2, and POT1. The POT1 connection
occurs via TPP1 (gene name ACD).17,39–42 TIN2, POT1,
and TPP1 interactions in the cytoplasm were also found
to regulate the assembly and function of the shelterin com-
plex (also referred to as the telosome) in the nucleus.43 In
that study, Chen et al. proposed that TIN2 could be a limit-
ing factor in telosome formation, in terms of both bridging
different subcomplexes and regulating their localization.
The mutated region of TIN2 in DC patients is near the
end of its TRF1-binding domain.40,42,44 Kim et al. showed
that the TIN2-15C mutant, containing only amino acids
1–257, resulted in loss of TRF1 binding to TIN2.40 There-
fore, it is possible that disruption of this domain by the
mutations in amino acids 280 and 282 will lead to altered
TRF1 binding to TIN2, thereby disrupting the TIN2-TRF1-
TRF2 complex and resulting in telomeric instability. TIN2
binding partners and its 3D structure are active areas of
investigation.
Other than a genetic association study that suggested
an increased risk for acquired aplastic anemia in individ-
uals with a variant allele in intron 9 of the TRF1 gene
(TERF1),45 the role of germline polymorphisms or muta-
tions in proteins of the shelterin telomere protection com-
plex is predominantly unexplored.
The clinical spectrum of DC is broad, ranging from the
diagnosis of a severe phenotype during infancy to more
subtle cases that present in adulthood.2,3 Therefore, we
chose to deﬁne the affected phenotype for the linkage
study as individuals with telomeres in leukocyte subsets
less than the ﬁrst percentile because this was shown to
be a sensitive and speciﬁc test to differentiate DC patients
from healthy relatives and other IBMFS patients.12 This
approach, in a clinically heterogeneous family, identiﬁed
a previously unreported DC susceptibility gene, TINF2.
This further illustrates the utility of telomere lengths that
are less than the ﬁrst percentile as a diagnostic test for
DC in the setting of variable clinical phenotypes.
Four of eight additional unrelated probands with clinical
DC and very short telomere lengths but no mutations in
DKC1, TERC, or TERT were heterozygous for mutations
in TINF2 (R282H and R282S). In total, TINF2 mutations
were present in ﬁve out of nine (56%) previously mole-
cularly uncharacterized DC probands, including the pro-
bands, family A III-07, B-1, C-1, D-1, and E-1. The muta-
tions in DC probands represented in our patients are
DKC1 (18.8%), TERC (18.8%), TERT (6.2%), and TINF2
(31.2%). Four patients (25%) remain unclassiﬁed at the
molecular level. Larger studies that would determine the
prevalence of TINF2 mutations in DC are warranted.
By focusing on very short telomere lengths in leukocyte
subsets as the affected phenotype, instead of the heteroge-The Ameneous clinical features present in DC patients, we achieved
sufﬁcient statistical power to permit our mapping and
identifying a previously unreported DC gene, TINF2. This
strategy also provided important further validation of telo-
mere length as a diagnostic test for DC. This study demon-
strates that TINF2 is the ﬁfth gene mutated in DC, the ﬁrst
in Revesz syndrome, and the ﬁrst shelterin complex gene
mutated in human disease.Acknowledgments
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